CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-08-16 | Labrucherie Gil M SVP & Chief Financial Officer | Returned to the company | −8,207 | $58.40 | $479K | 113,059 |
| 2018-08-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Returned to the company | −5,946 | $58.40 | $347K | 85,723 |
| 2018-08-16 | ROBIN HOWARD W President & CEO | Returned to the company | −20,389 | $58.40 | $1.2M | 264,467 |
| 2018-08-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Returned to the company | −6,701 | $58.40 | $391K | 83,258 |
| 2018-08-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award | +10,400 | 76,148 | ||
| 2018-08-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award · Stock Option | +26,250 | 26,250 | ||
| 2018-08-15 | Nicholson John SVP & Chief Operating Officer | Grant or award | +26,000 | 188,596 | ||
| 2018-08-15 | Nicholson John SVP & Chief Operating Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2018-08-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award | +26,000 | 121,266 | ||
| 2018-08-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2018-08-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award | +15,000 | 91,669 | ||
| 2018-08-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award · Stock Option | +37,500 | 37,500 | ||
| 2018-08-15 | ROBIN HOWARD W President & CEO | Grant or award | +60,500 | 284,856 | ||
| 2018-08-15 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +151,250 | 151,250 | ||
| 2018-08-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award | +26,000 | 89,959 | ||
| 2018-08-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2018-08-14 | ROBIN HOWARD W President & CEO | Grant or award | +40,000 | $10.69 | $428K | 264,356 |
| 2018-08-14 | ROBIN HOWARD W President & CEO | Returned to the company | −40,000 | $60.08 | $2.4M | 224,356 |
| 2018-08-14 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −40,000 | 0 | ||
| 2018-08-14 | WINGER DENNIS L Director | Sale | −17,125 | $60.15 | $1.0M | 42,750 |
Page 30 of 43 · 847 trades